As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

CORE Kidney ... from baseline to week 12. Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk ...

Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions, kidney diseases and ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

The first kidney or cardiorenal outcome trial ... Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly), not only produced greater blood glucose reduction, but also greater weight loss ...

Recently, Eli Lilly announced ... sleep apnea. Tirzepatide is being investigated for four additional indications, including cardiovascular risk factors, chronic kidney disease, and metabolic ...

Eli Lilly is also exploring the potential of tirzepatide for other indications ... downstream applications such as sleep apnea, kidney disease, and heart failure. This strategy could open up ...